Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Polyrizon Ltd. ( (PLRZ) ) has shared an announcement.
On January 5, 2026, Polyrizon Ltd. reported positive in-vitro pre-clinical results showing that its PL-14 intranasal Allergy Blocker significantly outperformed hydroxypropyl methylcellulose (HPMC), a standard nasal barrier comparator, in blocking Der p 1, a key house dust mite allergen associated with allergic rhinitis and asthma. Using a validated Transwell permeability model that mimics allergen transfer into nasal mucosa, PL-14 demonstrated markedly lower allergen penetration than HPMC at all measured time points (1, 2, 4, 6 and 24 hours), with p-values of 0.0042 or better; allergen levels with PL-14 remained very low, rising only to about 141.2 ng at their peak versus more than 5,200 ng with HPMC at 24 hours. Management said the data provide important confirmation of PL-14’s barrier performance and support continued progression of the program toward clinical studies, a step that could strengthen Polyrizon’s positioning in the preventive allergy treatment space and signal potential value for patients, clinicians and investors if similar efficacy is demonstrated in humans.
More about Polyrizon Ltd.
Polyrizon Ltd. is a pre-clinical-stage biotechnology company specializing in innovative intranasal medical device hydrogels delivered as nasal sprays, designed to form a thin hydrogel-based “biological mask” in the nasal cavity that blocks contact between viruses or allergens and nasal epithelial tissue. The company’s proprietary Capture and Contain (C&C) hydrogel technology aims to enhance bioadhesion and prolonged retention for barrier protection and intranasal drug delivery, while its earlier-stage Trap and Target (T&T) platform focuses on nasal delivery of active pharmaceutical ingredients, positioning Polyrizon in the allergy and respiratory protection market segments.
Average Trading Volume: 3,150,319
Technical Sentiment Signal: Sell
Current Market Cap: $20.32M
Learn more about PLRZ stock on TipRanks’ Stock Analysis page.